Title (en) Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712

Title (de) Behandlung von L-DOPA-induzierter Dyskinesie mit OPC-14523 oder OPC-34712

Title (fr) Traitement de la dyskinésie induite par L-DOPA avec OPC-14523 ou OPC-34712

Publication EP 2792359 A1 20141022 (EN)

Application EP 13002077 A 20130419

Priority EP 13002077 A 20130419

Abstract (en) The present invention relates to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients.

IPC 8 full level A61K 31/496 (2006.01); A61P 21/00 (2006.01); A61P 25/14 (2006.01); A61P 43/00 (2006.01)

CPC (source: EP) A61K 31/496 (2013.01); A61P 21/00 (2018.01); A61P 25/14 (2018.01); A61P 43/00 (2018.01)

Citation (applicant) • WO 2010000020 A1 20100107 - CATHRX LTD [AU], et al • WO 2006000020 A1 20060105 - EUROP NICKEL PLC [GB], et al • WO 2004000020 A1 20031231 - BAYER CROPSCIENCE AG [DE], et al • WO 2005000020 A2 20050106 - COGNIS CORP [US], et al • SNOW BJ ET AL.: "The effect of amantadine on levodopa- induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study", CLIN NEUROPHARMACOL, vol. 23, no. 2, 2000, pages 82 - 5, XP009171876, DOI: doi:10.1097/00002826-200003000-00004 • WARREN; BURN, ADVANCES IN CLINICAL NEUROSCIENCES AND REHABILITATION, vol. 4, 2004, pages 38 - 41 • CARTA M; CARLSSON T; KIRIK D; BJ6RKLUND A.: "Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats", BRAIN, vol. 130, 2007, pages 1819 - 1833, XP002541433, DOI: doi:10.1093/brain/awm082 • IRAVANI MM; JACKSON MJ; KUOPPAMAKI M; SMITH LA; JENNER P.: "3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates", J NEUROSCI., vol. 23, 2003, pages 9107 - 9115, XP002308002 • SCHIPPER J; TULP MTM; SIJBESMA H.: "Neurochemical profile of Eltoprazine", DRUG METABOLISM AND DRUG INTERACTIONS, vol. 8, 1990, pages 85 - 114 • OSHIRO ET AL.: "3,4-dihydro-2(1 H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1- piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1 H)-quinolinone and its derivatives", J MED CHEM., vol. 43, 2000, pages 177 - 89 • TOTTORI ET AL.: "Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523", NEUROPHARMACOLOGY, vol. 41, 2001, pages 976 - 88 • "VHD; Cosyns B Drug-induced valvular heart disease", HEART, vol. 99, no. 1, 2013, pages 7 - 12 • ROTHMAN; BAUMANN, EXPERT OPIN DRUG SAF., vol. 8, no. 3, May 2009 (2009-05-01), pages 317 - 29 • ZANETTINI R ET AL.: "Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease", N ENGL J MED, vol. 356, 2007, pages 39 - 46 • ELANGBAM C: "Drug-induced Valvulopathy: An Update", TOXICOLOGIC PATHOLOGY, vol. 38, 2010, pages 837 - 848 • HUANG X-P ET AL.: "Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine 2B Receptor Agonists: Implications for Drug Safety Assessment", MOL PHARMACOL, vol. 76, 2009, pages 710 - 722 • SETOLA V ET AL.: "3,4-Methylenedioxymethamphetamine (MDMA, ''Ecstasy'') Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro", MOL PHARMACOL, vol. 63, 2003, pages 1223 - 1229, XP002469125, DOI: doi:10.1124/mol.63.6.1223 • "FDA Guidance for Industry: Developing Products for Weight Management", DRAFT GUIDANCE, February 2007 (2007-02-01) • A.R. GENNARO: "Remington's Pharmaceutical Sciences" • CENCI MA; LEE CS; BJ6RKLUND A: "L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA", EUR J NEUROSCI, vol. 10, 1998, pages 2694 - 2706

Citation (search report) • [AD] WO 2010063486 A1 20100610 - MERZ PHARMA GMBH & CO KGAA [DE], et al • [AD] WO 2006112464 A1 20061026 - HASHIMOTO KAZUYA [JP], et al • [A] WO 2007045876 A1 20070426 - DANYSZ WOJCIECH [DE] • [A] WO 2011000562 A1 20110106 - MERZ PHARMA GMBH & CO KGAA [DE], et al • [A] WO 2007096164 A2 20070830 - MERZ PHARMA GMBH & CO KGAA [DE], et al

Cited by CN106994119A

Designated contracting state (EPC) AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC) BA ME

DOCDB simple family (publication) EP 2792359 A1 20141022

DOCDB simple family (application) EP 13002077 A 20130419